•  
  •  
  •  
  •  

2026-08-12 19:29:21

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT

Keywords Selected:  AstraZenecaPharmaIndia

Stock Report

  • AstraZeneca Pharma India Starts FY2026-27 with 30% Operational Revenue Growth Driven by Core Therapies
  • AstraZeneca Pharma India Ltd receives permission from CDSCO for Datopotamab Deruxtecan powder
  • AstraZeneca Pharma India Ltd and Sun Pharma partner to help patients living with Hyperkalaemia in India
  • AstraZeneca Pharma India Ltd to launch Sodium Zirconium Cyclosilicate powder in Nov 2025
  • AstraZeneca Pharma India Ltd receives sale and distribution approval from CDSCO for Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder
  • AstraZeneca Pharma India Ltd receives permission from CDSCO for Durvalumab Solution
  • AstraZeneca Pharma India Ltd surrenders marketing authorisation for Olaparib 100mg and 150mg
  • AstraZeneca Pharma India Ltd to discontinue the manufacturing and marketing of Imdur from April 1, 2025
  • AstraZeneca Pharma India Ltd receives permission for Olaparib film-coated tablets
  • AstraZeneca Pharma India Ltd to launch Breztri Aerosphere in January 2025 in India
  • AstraZeneca Pharma India Ltd to launch Tremelimumab
  • AstraZeneca Pharma India Ltd to launch Palivizumab in India
  • AstraZeneca Pharma India Ltd updates on exploring contract manufacturer
  • AstraZeneca Pharma India Limited achieves growth of 29% for financial year ended March 31, 2024
  • AstraZeneca Pharma India Ltd and Mankind Pharma partner to accelerate access to asthma medicine for patients in India
  • AstraZeneca Pharma India Ltd receives permission to import new drug
  • AstraZeneca Pharma India Ltd to launch Enhertu in January 2024
  • AstraZeneca Pharma India Ltd receives permission from CDSCO to import new drug
  • AstraZeneca Pharma India Ltd receives permission to Import pharmaceutical formulations of new drug for sale
  • AstraZeneca Pharma India receives permission to import Palivizumab solution for injection
  • AstraZeneca Pharma India Ltd Q1 FY2024 PAT climbs to Rs. 53.86 crore
  • AstraZeneca Pharma India Ltd receives permission from DCGI for Dapagliflozin Tablets 10 mg
  • AstraZeneca Pharma India Ltd receives permission for sale and distribution of Trastuzumab deruxtecan
  • AstraZeneca Pharma India Ltd Q3 FY2022-23 PAT at Rs. 29.30 crores

Latest Post

  • Enviro Infra Engineers Reports 49.1% Revenue Growth to ₹ 3,592 Million in Q1 FY27; PAT Rises 6.5% to ₹ 452 Million
  • Wanbury Limited Reports Q1 FY27 Revenue of ₹165.6 Crore; Refinances ₹205 Crore Debt to Cut Interest Costs
  • Popular Vehicles & Services Reports 44.6% YoY Revenue Growth to ₹1,903.1 Crore in Q1 FY27; Turns Profitable with ₹1.4 Crore PAT
  • Hirect Limited Reports 20.3% Revenue Growth in Q1 FY27; Standalone Net Profit Up 17.8% Amid Global Expansion
  • Delton Cables reports highest ever first quarterly Revenue, EBITDA & PAT


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025